Genmab — Juni 2017
-
HuMax-AXL-ADC is an ADC targeted to AXL, a signaling molecule expressed on many solid cancers and implicated in tumor biology. HuMax-AXL-ADC is in Phase I/II clinical development for six different solid tumors. HuMax-AXL-ADC is fully owned by Genmab and the ADC technology used with HuMax-AXL- ADC was licensed from Seattle Genetics.
-
Ovarian Cancer
Cervical Cancer
Endometrial Cancer
NSCLC
Thyroid Cancer
Melanoma -
GB. Pom godkendelsen gav ikke anledning til ændring af guidance. Om den var indregnet er en helt anden ting. De fleste ceo'er er ikke begejstrede for at ændre guidance mm de er 100pct sikre på ikke at skulle omgøre det
-
NBI oppe med 2.35%, kan give lidt medvind
-
Har desværre ikke selv adgang til artiklen. http://medwatch.dk/secure/Medicinal___Biotek/article9663190.ece
-
-
Nu må der være likviditet til Tisotumab https://endpts.com/slammed-by-more-deaths-seattle-genetics-scraps-a-phiii-study-and-pulls-back-again-on-vadastuximab/
-
AE 5??
-
dødsfald?
-
Godmorgen, det bliver vist en dejlig dag, solen skinner, Biotek index
i US steg og futures er også positive
-
God morgen.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind